RHBDF2 and metabolic dysfunction-associated steatohepatitis: These proof‐of‐principle works echo results from our above genetic mice models with NASH, indicating that, again, the ZDHHC3‐IRHOM2 axis is central to the progression of NASH, and thus targeting hepatocyte ZDHHC3 and development of ZDHHC3‐based specific drugs may have the ability to retard NASH progression and its associated complications.